ads_id stringlengths 8 8 | arxiv_id int64 0 999 | title stringlengths 0 236 | abstract stringlengths 0 4.26k ⌀ | embed sequencelengths 1.54k 1.54k | date date32 | cites int64 1 1.16k | bibcode stringlengths 8 8 | keywords sequencelengths 0 30 | ads_keywords sequencelengths 0 14 | read_count int64 0 0 | doi stringlengths 13 16.8k ⌀ | authors sequencelengths 0 66 | aff sequencelengths 0 66 | cite_bibcodes sequencelengths 1 1.16k | ref_bibcodes sequencelengths 0 0 | umap_x float32 4.76 33.7 | umap_y float32 2.73 7.65 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
39844819 | 0 | Advancements and Future Directions of Dual-Target Chimeric Antigen Receptor T-Cell Therapy in Preclinical and Clinical Studies. | In recent years, chimeric antigen receptor T-cell (CAR-T) therapy has made groundbreaking progress in the treatment of various cancer types, particularly hematological malignancies. In the meantime, various preclinical and clinical studies have extensively explored dual-target CAR-T therapies which can be designed to recognize two antigens simultaneously based on the immunophenotype of tumor cells. Compared with single-target CAR-T approach, dual-target CAR-T therapies demonstrate varying degrees of superior antitumor CAR effects, prevent antigen escape and relapse, reduce on-target off-tumor effects, and ensure durable responses in different types of cancer. These advantages highlight the potential future prospects in this field, showing varying degrees of advancement in preclinical and clinical studies. Herein, we aimed to review different dual-target CAR-T studies conducted on a wide range of tumor models, summarizing the selection of target combinations, the efficacy and safety demonstrated in preclinical and clinical settings, the existing limitations, and the potential future directions of this promising therapeutic strategy. | [
0.021476397290825844,
-0.012967296876013279,
0.059178426861763,
0.059794869273900986,
-0.04632120952010155,
-0.00737528782337904,
-0.003563805017620325,
0.04000268131494522,
-0.00974198430776596,
0.004645330365747213,
-0.0049122716300189495,
-0.02718949317932129,
-0.029831387102603912,
0.0... | 2025-01-23 | 63 | 39844819 | [
"target combinations",
"target",
"superior antitumor CAR effects",
"various cancer types",
"antigen escape",
"tumor cells",
"varying degrees",
"tumor models",
"different types",
"tumor",
"different dual-target CAR-T studies",
"dual-target CAR-T therapies",
"various preclinical and clinical s... | [
"cancer immunotherapy",
"dual-target CAR-T",
"hematological malignancies",
"solid tumors"
] | 0 | 10.1155/jimr/5845167
10.1073/pnas.90.2.720
10.1038/s41591-019-0564-6
10.1182/blood.2019001641
10.1182/blood-2017-02-769208
10.1038/s41591-019-0549-5
10.1016/j.ajodo.2021.06.028
10.1172/JCI85309
10.1056/NEJMoa1709866
10.1182/bloodadvances.2020003092
10.3389/fimmu.2019.02664
10.1016/j.annonc.2020.10.478
10.1182/blood.2020006245
10.1056/NEJMoa1709919
10.1158/2159-8290.CD-15-1020
10.1182/blood-2015-08-665547
10.1200/JCO.2018.77.8084
10.1172/JCI126397
10.1038/nm.4441
10.1182/blood-2016-04-711903
10.1056/NEJMoa2024850
10.1038/nature12625
10.1158/2159-8290.CD-18-0442
10.1126/scitranslmed.aaa0984
10.1007/s10875-012-9689-9
10.1182/blood.2019003293
10.1182/blood.2019000017
10.1038/s41591-021-01436-0
10.1038/s41375-021-01232-2
10.1038/s41467-021-26683-0
10.1038/s41375-018-0075-3
10.1182/blood-2013-09-529537
10.1200/JCO.2018.77.7250
10.1182/blood-2015-08-661702
10.1172/JCI94306
10.1182/blood.2019002779
10.3389/fonc.2019.01350
10.3389/fonc.2019.00146
10.1186/s13045-019-0758-x
10.3390/cancers12092523
10.1158/2326-6066.CIR-13-0008
10.1126/scitranslmed.3006597
10.1016/j.cell.2018.03.038
10.1158/2326-6066.CIR-20-0675
10.1007/s13577-023-00934-2
10.1186/s13045-020-00856-8
10.1182/bloodadvances.2022008559
10.1158/2159-8290.CD-22-0964
10.1016/j.jcyt.2017.09.005
10.1182/blood.2020005278
10.1182/blood-2018-04-842708
10.1111/j.1365-2141.2010.08297.x
10.1016/j.omto.2023.100751
10.1111/ejh.14104
10.1038/s41392-022-00898-z
10.1016/j.omto.2023.07.007
10.1158/2643-3230.BCD-22-0074
10.1038/s41467-024-47801-8
10.1186/s13046-021-02214-z
10.1186/s13045-021-01170-7
10.3389/fimmu.2022.898341
10.1038/s41467-023-39395-4
10.1038/s41467-020-16160-5
10.1182/blood-2017-05-781351
10.1158/2326-6066.CIR-21-0062
10.1186/s12885-020-07180-x
10.1016/j.jcyt.2020.01.008
10.3389/fonc.2022.954345
10.1002/cam4.3259
10.1016/S2352-3026(19)30115-2
10.1111/cas.14799
10.1016/S1470-2045(18)30864-7
10.1016/S1470-2045(21)00375-2
10.1038/s41408-023-00819-5
10.1002/ajh.25235
10.1182/blood-2012-06-438002
10.1158/2159-8290.CD-19-0945
10.1158/1078-0432.CCR-18-3784
10.1016/j.omto.2018.10.006
10.1007/s12032-011-9955-3
10.1038/sj.onc.1206939
10.1038/s41586-021-03819-2
10.1016/j.jbiotec.2010.07.010
10.1089/104303401753153947
10.1136/jitc-2021-002721
10.1111/cei.12279
10.1007/s00277-008-0535-3
10.12659/MSM.884017
10.1038/s41598-019-46938-7
10.3389/fimmu.2024.1422478
10.21037/tcr-22-174 | [
"Zhang",
"Liu"
] | [
"School of Medicine, University of Tsinghua, Beijing, China.\nDivision of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.",
"Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA."
] | [
"39844819",
"31650176",
"28408462",
"36127190",
"27111235",
"29385370",
"33147337",
"33098993",
"33156925",
"29385376",
"26516065",
"26907630",
"29812997",
"30896447",
"27412889",
"33626253",
"24048066",
"30135176",
"22526592",
"31725148",
"31697824",
"33833386",
"2951523... | [] | 8.246161 | 4.160666 |
39844295 | 1 | Application of adoptive cell therapy in malignant melanoma. | Cutaneous melanoma is one of the most aggressive skin cancers originating from skin pigment cells. Patients with advanced melanoma suffer a poor prognosis and generally cannot benefit well from surgical resection and chemo/target therapy due to metastasis and drug resistance. Thus, adoptive cell therapy (ACT), employing immune cells with specific tumor-recognizing receptors, has emerged as a promising therapeutic approach to display on-tumor toxicity. This review discusses the application, efficacy, limitations, as well as future prospects of four commonly utilized approaches -including tumor-infiltrating lymphocytes, chimeric antigen receptor (CAR) T cell, engineered T-cell receptor T cells, and chimeric antigen receptor NK cells- in the context of malignant melanoma. | [
-0.0025810925289988518,
0.042373497039079666,
0.051993075758218765,
0.05337037518620491,
-0.00657445564866066,
0.0006899950094521046,
-0.004960432182997465,
0.029482828453183174,
0.007505209185183048,
-0.003752604592591524,
0.02045505680143833,
-0.051993075758218765,
-0.030429722741246223,
... | 2025-01-23 | 112 | 39844295 | [
"chimeric antigen receptor",
"adoptive cell therapy",
"skin pigment cells",
"immune cells",
"T cell",
"engineered T-cell receptor T cells",
"advanced melanoma",
"malignant melanoma",
"Cutaneous melanoma",
"tumor",
"surgical resection",
"future prospects",
"specific tumor-recognizing receptor... | [
"Adoptive Cell Therapy",
"Chimeric Antigen Receptors (CARs)-T cell",
"Malignant Melanoma",
"Natural Killer (NK) Cells",
"T-cell Receptors",
"Tumor-infiltrating Lymphocytes"
] | 0 | 10.1186/s12967-025-06093-2
10.3322/caac.21492
10.3322/caac.21332
10.3322/caac.21352
10.3390/ijms242115881
10.1016/j.critrevonc.2020.103208
10.1016/S0140-6736(21)01206-X
10.1080/21645515.2021.1971015
10.1016/j.clinthera.2015.02.018
10.1056/NEJMoa1504030
10.1056/NEJMoa1910836
10.1186/s13578-023-01073-9
10.1146/annurev-immunol-070621-030155
10.3390/diagnostics11081341
10.1038/nature13121
10.1038/cr.2014.67
10.1016/j.ejca.2016.04.005
10.1016/j.ccr.2012.02.022
10.1016/j.cell.2017.01.017
10.1016/j.ctrv.2016.11.007
10.1016/j.coi.2021.10.004
10.1007/s00428-018-2484-0
10.1159/000019050
10.1016/j.critrevonc.2017.05.001
10.1126/science.3489291
10.1016/S0022-1759(87)80018-2
10.1007/978-3-030-35723-8_4
10.1038/s43018-023-00521-2
10.1038/s41586-023-06199-x
10.1038/onc.2008.271
10.1016/j.retram.2023.103404
10.1371/journal.pone.0013940
10.1038/cgt.2014.81
10.1093/jnci/86.15.1159
10.1126/science.aaa4967
10.3389/fimmu.2021.690499
10.1200/JCO.2008.16.5449
10.1200/JCO.2005.00.240
10.1136/jitc-2020-001743
10.1200/JCO.1999.17.7.2105
10.1111/imm.13194
10.1158/1078-0432.CCR-11-0116
10.1200/JCO.21.00612
10.1056/NEJMoa2210233
10.1158/1078-0432.CCR-10-0041
10.1097/CJI.0b013e31818403d5
10.1371/journal.pone.0004749
10.1158/1078-0432.CCR-14-1934
10.1038/s41551-021-00820-y
10.3390/ijms242115688
10.1002/ajh.25418
10.1016/j.ebiom.2022.103941
10.1073/pnas.91.10.4318
10.1073/pnas.90.2.720
10.1038/nri3405
10.1136/jitc-2021-003354
10.1038/sj.leu.2403302
10.1111/imr.12125
10.1186/s12943-022-01559-z
10.1158/0008-5472.CAN-18-3158
10.1038/s41408-020-00405-z
10.1016/j.omto.2020.03.019
10.1038/s41586-019-0985-x
10.1158/2767-9764.CRC-22-0486
10.1038/s41467-024-45221-2
10.7150/thno.43991
10.1136/jitc-2020-002151
10.3389/fimmu.2022.835762
10.1016/j.cell.2020.03.001
10.1111/imr.12644
10.3390/cells9061485
10.1084/jem.179.3.1005
10.1073/pnas.91.9.3515
10.4049/jimmunol.169.1.575
10.1038/modpathol.3800232
10.1158/0008-5472.CAN-09-0494
10.1126/science.1129003
10.1038/gt.2009.54
10.1080/10409238.2017.1304354
10.1182/blood-2017-05-787598
10.1007/978-1-0716-0290-4_23
10.1016/j.intimp.2022.109055
10.1182/blood-2009-03-211714
10.1006/jsre.2001.6148
10.1002/ijc.2910630313
10.1007/s00403-004-0527-7
10.1200/JCO.2010.32.2537
10.1097/CJI.0b013e3182829903
10.1126/sciadv.adf3700
10.1080/2162402X.2018.1532759
10.1038/s41591-020-01225-1
10.1016/j.ymthe.2020.09.015
10.1016/S2352-3026(20)30277-5
10.1038/s41568-020-00323-z
10.3389/fimmu.2022.795164
10.1038/s41573-019-0052-1
10.3389/fimmu.2018.01869
10.1182/blood-2004-07-2974
10.1126/science.1068440
10.1056/NEJMoa1910607
10.3390/cancers14153839
10.3390/ijms22115899
10.1038/leu.2017.226
10.1182/blood.2020007748
10.1016/j.it.2013.03.002
10.1073/pnas.1012356108
10.1111/j.1365-2567.2008.03027.x
10.1038/s41598-019-40933-8
10.1038/ncomms6639
10.3390/cancers13061363
10.3389/fonc.2019.01529
10.3389/fimmu.2023.1212546 | [
"Hu",
"Xuan",
"Wang",
"Shen",
"Gao",
"Zhou",
"Wei",
"Gu"
] | [
"Department of Plastic and Reconstructive Surgery, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, People's Republic of China.",
"Department of Plastic and Reconstructive Surgery, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, People's Republic of China.",
"D... | [
"39844295",
"30207593",
"26742998",
"27232110",
"37958863",
"33383207",
"34509219",
"34882516",
"25823918",
"26027431",
"31562797",
"37386520",
"35471840",
"34441278",
"24670642",
"24853952",
"27232329",
"22439926",
"28187290",
"27951441",
"34743069",
"30470934",
"9619397... | [] | 10.290885 | 4.705851 |
39844281 | 2 | Knockout IL4I1 affects macrophages to improve poor efficacy of CD19 CAR-T combined with PD-1 inhibitor in relapsed/refractory diffuse large B-cell lymphoma. | Chimeric antigen receptor (CAR) T-cell therapy plays a critical role in the treatment of B-cell hematologic malignancies. The combination of PD-1 inhibitors and CAR-T has shown encouraging results in treating patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). However, there are still cases where treatment is ineffective. This study aimed to investigate the role of IL4I1 in the poor efficacy of CD19 CAR-T combined with PD-1 inhibitors in R/R DLBCL and to explore potential mechanisms. Transcriptomic and metabolomic correlation analyses were performed on tumor tissue from DLBCL patients. We employed an in vitro co-culture system consisting of Pfeiffer cells, CD19 CAR-T and macrophages to investigate the underlying mechanisms. It was found that IL4I1 levels were significantly increased in the tumor tissues of R/R DLBCL patients compared to responders. Correlation analysis revealed a positive association between IL4I1 and tryptophan (Trp)-kynurenic acid (Kyn) related metabolites. In the in vitro co-culture model, the presence of IL4I1 inhibited the cytotoxicity of CAR-T cells. Depletion of IL4I1 disrupted the IDO-AHR-Kyn signaling pathway, thereby enhancing the effectiveness of PD-1 inhibitors in combination with CD19 CAR-T for DLBCL treatment. CAR-T-mediated cytotoxicity was significantly inhibited when IL4I1 was present in the in vitro co-culture model. These findings suggest that IL4I1 may be a contributing factor to poor prognosis in R/R DLBCL patients. IL4I1 expression enhances immunosuppression via the IDO-AHR-Kyn pathway, inhibiting the effectiveness of PD-1 inhibitors combined with CD19 CAR-T. Therefore, suppression of IL4I1 may represent a potential target for combination therapy in DLBCL. | [
0.006582936272025108,
-0.010425412096083164,
0.025771990418434143,
0.05952047184109688,
0.010011427104473114,
-0.0325123593211174,
0.0029110105242580175,
0.017853809520602226,
-0.013947195373475552,
0.003810406429693103,
-0.00629722885787487,
0.011200903914868832,
-0.05317659676074982,
0.0... | 2025-01-23 | 20 | 39844281 | [
"IL4I1 levels",
"IL4I1",
"DLBCL patients",
"R/R DLBCL patients",
"DLBCL treatment",
"Pfeiffer cells",
"R/R DLBCL",
"tumor tissue",
"combination therapy",
"Correlation analysis",
"CD19 CAR-T",
"Kyn",
"CD19 CAR-T. Therefore",
"poor prognosis",
"CAR-T cells",
"potential mechanisms",
"pa... | [
"CD19 CAR-T",
"DLBCL",
"IL4I1",
"Metabolism",
"PD-1 inhibitor"
] | 0 | 10.1186/s12967-024-06028-3
10.1056/NEJMoa011795
10.1016/j.blre.2023.101140
10.1056/NEJMoa1804980
10.1158/2643-3230.BCD-23-0056
10.1182/bloodadvances.2020003844
10.1136/jitc-2020-001466
10.1182/blood-2016-09-738245
10.1016/j.cell.2018.09.007
10.1158/1078-0432.CCR-20-1457
10.1016/j.tranon.2021.101085
10.3389/fonc.2019.00767
10.3389/fimmu.2022.994731
10.1182/blood-2023-173202
10.1186/s12967-021-03123-7
10.1016/j.cell.2020.07.038
10.1016/j.immuni.2016.01.018
10.1002/stem.2288
10.1016/j.immuni.2022.05.013
10.1038/s41586-022-05140-y
10.3389/fonc.2021.664421
10.1182/blood-2015-11-679134
10.3390/ijms19020340
10.1182/blood.2021012634
10.3390/cancers11040462
10.1016/j.cell.2018.09.007
10.7554/eLife.82934
10.1038/s41598-019-39553-z
10.1007/s12672-024-01000-5
10.1038/s41586-021-03442-1
10.1016/j.immuni.2017.12.012
10.1038/s41392-020-0188-9
10.1016/j.bcp.2020.113926
10.1158/1078-0432.CCR-19-3874 | [
"Zhang",
"Zhang",
"Xiao",
"Liu",
"Zhao"
] | [
"Department of Hematology, Tianjin First Central Hospital, Tianjin, China.",
"Department of Hematology, First Center Clinic College of Tianjin Medical University, Tianjin, China.",
"Boyalife wsn ltd, Shen Zhen, China.",
"Boyalife wsn ltd, Shen Zhen, China. liuqingxi66@aliyun.com.",
"Department of Hematology... | [
"39844281",
"11807147",
"30501490",
"33414262",
"28031179",
"30290143",
"33028589",
"31482064",
"36275688",
"32818467",
"26885856",
"26850336",
"35704993",
"36045296",
"34113569",
"26813675",
"30290143",
"36779699",
"33828302",
"32217098"
] | [] | 7.412257 | 5.586925 |
39843688 | 3 | Evolving Immunotherapy Strategies in Gastrointestinal Neuroendocrine Neoplasms. | Treatment for neuroendocrine neoplasms (NENs) is tailored to the tumor's site of origin, grade, and differentiation. NENs are categorized into two main types: well-differentiated neuroendocrine tumors (NETs), which tend to grow more slowly and are less aggressive, and poorly differentiated neuroendocrine carcinomas (NECs), which are highly aggressive and harder to treat. Treatment options for NETs range from somatostatin analogues and mTOR inhibitors to peptide receptor radionuclide therapy (PRRT) with Lutetium-177 dotatate. In cases where the disease progresses more rapidly, cytotoxic chemotherapy may also be considered. In contrast, chemotherapy plays a central role in treating NECs, often following protocols similar to those used for small cell lung cancer. Exciting progress is being made in the development of new therapies for NENs. Inspired by the success of immunotherapy in other cancers, clinical trials have begun to explore its potential in NENs. Early findings suggest that immune checkpoint inhibitors (ICIs) may offer benefits, especially in patients with higher-grade NETs and NECs. However, because NENs have an immunologically "cold" tumor microenvironment-meaning they are less likely to trigger an immune response-new strategies are needed to boost ICI efficacy. To overcome this challenge, researchers are exploring innovative approaches, such as combining dual ICIs or pairing ICIs with other therapeutic agents to make the tumors more responsive to immune attack. Moreover, there is growing enthusiasm for cutting-edge therapies designed to enhance the immune system's ability to recognize and destroy cancer cells. These include bispecific T cell engagers, chimeric antigen receptor T cells, tumor-infiltrating lymphocytes, oncolytic viruses, and cancer vaccines. While their effectiveness in NENs is still being studied, these approaches hold considerable promise, offering new hope for patients with this challenging and complex cancer type. | [
-0.005444354843348265,
-0.00921536237001419,
0.05976240336894989,
0.04035157337784767,
-0.002009510761126876,
0.02543487958610058,
0.029546532779932022,
0.03540324792265892,
0.003908460959792137,
0.024024486541748047,
0.01702033169567585,
-0.021442750468850136,
-0.00969346147030592,
0.0119... | 2025-01-23 | 60 | 39843688 | [
"cancer cells",
"small cell lung cancer",
"immune checkpoint inhibitors",
"new therapies",
"other cancers",
"chimeric antigen receptor T cells",
"receptor radionuclide therapy",
"bispecific T cell engagers",
"immune attack",
"NENs",
"cancer vaccines",
"new hope",
"other therapeutic agents",
... | [
"Gastroenteropancreatic neuroendocrine cancers",
"Immune checkpoint inhibitors",
"Immunotherapy",
"Neuroendocrine carcinoma",
"Neuroendocrine tumor"
] | 0 | 10.1007/s11864-024-01283-4
10.1007/s00428-006-0250-1
10.1007/s00428-007-0452-1
10.1093/annonc/mds276
10.1111/cas.12473
10.1111/jne.13249
10.1056/NEJMoa1809064
10.1016/S0140-6736(19)32222-6
10.7150/jca.13711
10.1002/cncr.32883
10.1530/ERC-20-0382
10.1158/1078-0432.CCR-19-3014
10.1158/1078-0432.CCR-19-3356
10.1002/cncr.33591
10.1038/s41467-023-38611-5
10.1038/s41467-024-50969-8
10.1158/1078-0432.CCR-20-0621
10.1016/j.lungcan.2020.03.008
10.1136/jitc-2020-000980
10.1158/1078-0432.CCR-14-1191
10.3389/fonc.2021.729765
10.1007/s12022-020-09657-8
10.1093/oncolo/oyac161
10.1158/1078-0432.CCR-18-1278
10.1267/ahc.12006
10.1038/s41698-021-00214-y
10.1056/NEJMoa2307980
10.1016/j.lungcan.2020.04.017
10.1136/jitc-2022-SITC2022.0697
10.1002/JLB.5MA0122-467R
10.1016/j.jtho.2018.10.003
10.1016/j.jtho.2019.12.109
10.1186/s13045-023-01464-y
10.1016/j.annonc.2023.09.672
10.1158/2159-8290.CD-12-0548
10.1111/his.12610
10.1038/s43018-022-00344-7
10.1136/jitc-2023-SITC2023.0702
10.1136/jitc-2022-004854
10.3390/cells8080880
10.3390/cancers13061339
10.1158/0008-5472.CAN-17-0299
10.1200/JCO.21.00612
10.1158/2159-8290.CD-23-1334
10.1136/jitc-2020-001188
10.1159/000518106
10.1158/1078-0432.CCR-10-1706
10.1002/cam4.1185
10.1158/1078-0432.CCR-06-2532
10.1159/000448430
10.1159/000500159
10.18632/oncotarget.27391
10.1186/s12885-020-07121-8
10.1158/0008-5472.CAN-15-3308
10.1200/JCO.2017.73.7379
10.1038/s41392-023-01674-3
10.1038/25141
10.1007/s00432-022-04013-1
10.18632/oncotarget.27631
10.1007/s00262-016-1890-x
10.1200/JCO.22.00996 | [
"Urman",
"Schonman",
"De Jesus-Acosta"
] | [
"The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.",
"Johns Hopkins Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.",
"The Sidney Kimmel Comprehensive ... | [
"39843688",
"16967267",
"17674042",
"22967994",
"24975505",
"36924180",
"30280641",
"31590988",
"26958083",
"32320048",
"33480358",
"31980466",
"31969335",
"33882143",
"37221181",
"39117670",
"32532787",
"32203769",
"33428585",
"25991820",
"34568063",
"33409812",
"3598395... | [] | 11.116188 | 5.0375 |
39841845 | 4 | Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity. | A major limiting factor in the success of chimeric antigen receptor (CAR) T cell therapy for the treatment of solid tumors is targeting tumor antigens also found on normal tissues. CAR T cells against GD2 induced rapid, fatal neurotoxicity because of CAR recognition of GD2 | [
0.03570399805903435,
0.02385634556412697,
0.057282835245132446,
0.07232820242643356,
-0.03846461698412895,
-0.04488305747509003,
0.012629829347133636,
0.004790823440998793,
-0.02995271049439907,
-0.005112895742058754,
-0.020934689790010452,
-0.011813146993517876,
-0.035934049636125565,
0.0... | 2025-01-22 | 1 | 39841845 | [
"CAR T cells",
"tumor antigens",
"T cell therapy",
"chimeric antigen receptor",
"solid tumors",
"CAR recognition",
"GD2",
"normal tissues",
"CAR",
"rapid, fatal neurotoxicity",
"A major limiting factor",
"the success",
"the treatment"
] | [] | 0 | 10.1126/sciadv.ads3403 | [
"Vogt",
"Silberman",
"Lin",
"Han",
"Laflin",
"Gellineau",
"Heller",
"Scheinberg"
] | [
"Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.\nGraduate School of Medical Sciences, Weill Cornell Medicine, New York, NY 10065, USA.\nTri-Institutional PhD Program in Chemical Biology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.",
"Molecular... | [
"39841845"
] | [] | 9.616429 | 6.79694 |
39841806 | 5 | Triple knockdown of | "Chimeric antigen receptor (CAR)-T cell therapies have revolutionized the landscape of cancer treatm(...TRUNCATED) | [0.013676300644874573,0.025339338928461075,0.047948043793439865,0.07261629402637482,-0.0426719076931(...TRUNCATED) | 2025-01-22 | 1 | 39841806 | ["CAR)-T cell therapies","solid tumors","tumor","Chimeric antigen receptor","improved CAR-T cell the(...TRUNCATED) | [] | 0 | 10.1126/scitranslmed.adl6432 | ["Wang","Wu","Cui","Bian","Zheng","Zhu","Geng","Sun","Pan","Shi","Yi","Song","Li","Shen","Li","Shen"(...TRUNCATED) | ["Department of Interventional Oncology, Renji Hospital, Shanghai Jiao Tong University School of Med(...TRUNCATED) | [
"39841806"
] | [] | 8.998252 | 5.280612 |
39840882 | 6 | [Patient with diffuse large B-cell lymphoma: a good example of network in care.]. | "Chimeric Antigen Receptor T cell (CAR-T) therapy has revolutionized prognosis of patients with diff(...TRUNCATED) | [0.018854942172765732,0.02260638028383255,0.052886709570884705,0.06867451965808868,-0.02425603568553(...TRUNCATED) | 2025-01-22 | 1 | 39840882 | ["marginal zone lymphoma","holding therapy","early referral","complete remission","diffuse large B-c(...TRUNCATED) | [] | 0 | 10.1701/4416.44128 | [
"Tisi"
] | [
"UO Ematologia, Ospedale San Bortolo, Vicenza."
] | [
"39840882"
] | [] | 6.266233 | 5.473475 |
39839908 | 7 | "A bioluminescent reporter bioassay for in-process assessment of chimeric antigen receptor lentivira(...TRUNCATED) | "Chimeric antigen receptor (CAR)-T-cell therapy is a breakthrough in the field of cancer immunothera(...TRUNCATED) | [-0.0014690025709569454,-0.01320493035018444,-0.009483763948082924,0.024350037798285484,-0.019641874(...TRUNCATED) | 2025-01-22 | 22 | 39839908 | ["CAR LV","LV potency","LV MOA","LV quantification","T cells","activated T cells","patient T cells",(...TRUNCATED) | [
"CAR-T",
"bioassay",
"lentivirus",
"potency assay"
] | 0 | "10.1093/abt/tbae032\n10.1016/j.ebiom.2020.102931\n10.1038/nbt0102-70\n10.4049/jimmunol.172.1.104\n1(...TRUNCATED) | [
"Gilden",
"Stecha",
"Hartnett",
"Cong"
] | ["Research and Development, Promega Corp., Madison, WI 53711, United States.","Research and Developm(...TRUNCATED) | ["39839908","32739874","11753365","14688315","20683006","37215709","36253252","16836756","38282894",(...TRUNCATED) | [] | 8.165737 | 4.711771 |
39837618 | 8 | Art of TIL immunotherapy: SITC's perspective on demystifying a complex treatment. | "In a first for solid cancers, cellular immunotherapy has entered standard of care in the treatment (...TRUNCATED) | [-0.029780112206935883,0.007054430432617664,0.02348320372402668,0.03451462835073471,-0.0084570311009(...TRUNCATED) | 2025-01-22 | 61 | 39837618 | ["TIL immunotherapy","TIL manufacturing","TIL","clinical practice guidelines","underlying clinical r(...TRUNCATED) | ["Adoptive cell therapy - ACT","Cytokine","Immunotherapy","Surgery","Tumor infiltrating lymphocyte -(...TRUNCATED) | 0 | "10.1136/jitc-2024-010207\n10.1126/science.aad1253\n10.1172/JCI82416\n10.1016/j.ccell.2023.11.005\n1(...TRUNCATED) | ["Turcotte","Donia","Gastman","Besser","Brown","Coukos","Creelan","Mullinax","Sondak","Yang","Rohaan(...TRUNCATED) | ["Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada.","Department of Oncol(...TRUNCATED) | ["39837618","26516200","26389673","38039963","37820582","3489291","3264384","12242449","34413159","3(...TRUNCATED) | [] | 10.194453 | 4.454338 |
39836430 | 9 | "Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antig(...TRUNCATED) | "Orvacabtagene autoleucel (orva-cel; JCARH125), a CAR T-cell therapy targeting B-cell maturation ant(...TRUNCATED) | [0.03012278489768505,0.003520004218444228,0.03740132227540016,0.01596098765730858,-0.070713579654693(...TRUNCATED) | 2025-01-21 | 1 | 39836430 | ["CAR+ T cells","T cell biology","Traditional piecewise models","plasma cells","traditional models",(...TRUNCATED) | [] | 0 | 10.1158/1078-0432.CCR-24-2753 | [
"Hu",
"Li",
"Piasecki",
"Hosseyni",
"Yan",
"Liu",
"Ogasawara",
"Zhou",
"Cheng"
] | ["Bristol-Myers Squibb (United States), Princeton, New Jersey, United States.","Bristol-Myers Squibb(...TRUNCATED) | [
"39836430"
] | [] | 5.44703 | 5.483919 |
End of preview. Expand
in Data Studio
README.md exists but content is empty.
- Downloads last month
- 14
Size of downloaded dataset files:
11.1 MB
Size of the auto-converted Parquet files:
11.1 MB
Number of rows:
1,000